Furthermore, our results showed an association between higher expression of YKL40 and an increased median number of bevacizumab doses administered (p = 0.035, Table 6), which rose from 6 in patients with low YKL40 tumor expression in their primary tumor to 9.5 in patients with high expression. This evidence concerns the gene CHI3L1 and neoplasm.